Symtuza ([darunavir + cobicistat + emtricitabine + tenofovir alafenamide (TAF)]; Johnson & Johnson) is a once-daily single-tablet regimen (STR) combination of the protease inhibitor (PI) Prezista, the two nucleos(t)ide reverse transcriptase inhibitors (NRTIs), Emtriva (emtricitabine; Gilead) and TAF (Gilead), and the boosting agent Tybost (cobicistat; Gilead). Symtuza is the first STR containing a PI.
While its convenience as a STR and the high resistance barrier of darunavir position Symtuza as a good alternative for treatment-experienced patients who have generated resistance to other regimens, it will struggle to compete in the first-line setting due to its late launch, generic threats, and fierce competition from Triumeq ([dolutegravir + abacavir + lamivudine]; ViiV Healthcare) and Biktarvy ([bictegravir + emtricitabine + TAF]; Gilead).
4 Drug Overview
5 Product Profiles
5 Symtuza : HIV
LIST OF FIGURES
10 Figure 29: Datamonitor Healthcare’s drug assessment summary of Ofev for idiopathic pulmonary fibrosis
11 Figure 30: Datamonitor Healthcare’s drug assessment summary of Ofev for idiopathic pulmonary fibrosis
14 Figure 31: Ofev sales for idiopathic pulmonary fibrosis across the US, Japan, and five major EU markets, by country, 2016–25
LIST OF TABLES
6 Table 1: Symtuza drug profile
6 Table 2: Approval history of Symtuza for HIV in the US and five major EU markets
8 Table 3: Late-phase trials of Symtuza for HIV
9 Table 4: Symtuza for HIV – SWOT analysis
Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is Suite 1, 3rd Floor, 11 - 12 St. James's Square, London, England, SW1Y 4LB. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.